Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCapital LeasesCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesCurrent TaxesFinished GoodsGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxLong-Term InvestmentsNon-Current AssetsNon-Current Deferred Tax LiabilityNon-Current Deferred Tax LiabilityOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsPayablesPreferred SharesPrepaid AssetsProperty, Plant & Equipment (Net)Property, Plant & Equipment (Net)Raw MaterialsReceivablesReceivables - NetReceivables - OtherRetained EarningsShareholder's EquityShares OutstandingShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTreasury SharesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

CorMedix (CRMD) Liabilities and Shareholders Equity (2016 - 2025)

CorMedix (CRMD) has disclosed Liabilities and Shareholders Equity for 13 consecutive years, with $826.1 million as the latest value for Q4 2025.

  • Quarterly Liabilities and Shareholders Equity rose 595.14% to $826.1 million in Q4 2025 from the year-ago period, while the trailing twelve-month figure was $2.0 billion through Dec 2025, up 514.3% year-over-year, with the annual reading at $826.1 million for FY2025, 595.14% up from the prior year.
  • Liabilities and Shareholders Equity hit $826.1 million in Q4 2025 for CorMedix, up from $750.9 million in the prior quarter.
  • In the past five years, Liabilities and Shareholders Equity ranged from a high of $826.1 million in Q4 2025 to a low of $57.0 million in Q2 2023.
  • Historically, Liabilities and Shareholders Equity has averaged $161.9 million across 5 years, with a median of $75.4 million in 2021.
  • Biggest five-year swings in Liabilities and Shareholders Equity: decreased 22.94% in 2022 and later surged 867.78% in 2025.
  • Year by year, Liabilities and Shareholders Equity stood at $68.9 million in 2021, then decreased by 10.02% to $62.0 million in 2022, then soared by 47.38% to $91.4 million in 2023, then increased by 29.99% to $118.8 million in 2024, then soared by 595.14% to $826.1 million in 2025.
  • Business Quant data shows Liabilities and Shareholders Equity for CRMD at $826.1 million in Q4 2025, $750.9 million in Q3 2025, and $252.6 million in Q2 2025.